• FirefoxInstall the new Firefox »
  •  Dow Down0.06% Nasdaq Up0.42%

    Codexis, Inc. (CDXS)

    3.55 Up 0.05(1.43%) Feb 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Codexis, Inc.
    200 Penobscot Drive
    Redwood City, CA 94063
    United States - Map
    Phone: 650-421-8100
    Website: http://www.codexis.com

    Index Membership:N/A
    Full Time Employees:125

    Business Summary 

    Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Codexis, Inc.

    Corporate Governance 
    Codexis, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 10. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. John J. Nicols , 51
    Chief Exec. Officer, Pres and Director
    Mr. Douglas T. Sheehy J.D., 48
    Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec.
    Mr. Gordon T. B. Sangster , 62
    Chief Financial Officer and Sr. VP
    Dr. John H. Grate Ph.D., 62
    Chief Science Officer and Sr. VP of Science & Innovation
    Mr. Beaudry-Losique Jacques ,
    VP of Corp. Devel. & Strategy
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders